APA (7th ed.) Citation

MJ, W., BJ, N., LM, W., JJ, V. G., MJ, L., BA, N., . . . UT, S. (2023). Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neuro-oncology advances, 5(1), vdad123. https://doi.org/10.1093/noajnl/vdad123

Chicago Style (17th ed.) Citation

MJ, Webb, et al. "Withdrawal of Bevacizumab Is Associated with Rebound Growth of Vestibular Schwannomas in Neurofibromatosis Type 2-related Schwannomatosis Patients." Neuro-oncology Advances 5, no. 1 (2023): vdad123. https://doi.org/10.1093/noajnl/vdad123.

MLA (9th ed.) Citation

MJ, Webb, et al. "Withdrawal of Bevacizumab Is Associated with Rebound Growth of Vestibular Schwannomas in Neurofibromatosis Type 2-related Schwannomatosis Patients." Neuro-oncology Advances, vol. 5, no. 1, 2023, p. vdad123, https://doi.org/10.1093/noajnl/vdad123.